The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Investigating Polarity Proteins In Thymocytes- A Potential Role In Asymmetric Cell Division?
Funder
National Health and Medical Research Council
Funding Amount
$69,684.00
Summary
To protect us against infection, surveying immune cells will launch an attack against foreign cells by using complex signalling process to communicate with each other. A novel method in which immune cells differentiate to defend the body against infection has been recently discovered this year and this project will involve dissecting how this occurs. It will involve using state-of-the-art laser-based technologies, combined with studying immune events in cells and intact organs.
Advanced Anti-cancer Activities With Therapeutic Agents That Induce Tumor Cell Apoptosis And Antitumor Immune Responses.
Funder
National Health and Medical Research Council
Funding Amount
$85,701.00
Summary
The aim is to perform pre-clinical studies to identify new therapies for blood cancers. We will utilise three new anti-cancer agents that kill tumor cells and genetically engineered mice that develop cancer. We will determine if these three new agents kill the mouse tumor cells and activate anti-tumor immunity. The combined effect of killing blood cancer cells using new therapeutics, coupled with enhancing the anti-cancer immune response may hold the key to developing new treatments.